News

 

Contact Media Relations

Office telephone: +39 0331 581380
mediarelations@nmsgroup.it

We are ICT in Maastricht 2022

Where: MECC – Forum 100, 6229 GV Maastricht, Netherlands

When: September 18 to 21, 2022

The Dutch Society of Toxicology (NVT) is welcoming the global community to the XVIth International Congress of Toxicology in Maastricht, the Netherlands, from September 18 to 21, 2022.

Accelera s.r.l. will be present at the ICT in Maastricht Exhibition Booth # 37.

We look forward to see you soon!

Get an appointment with us! E-mail: Francesco.Sola@accelera.org

NMS Group S.p.A. Appoints Andrew Curtis as Chief Strategy Officer, Effective Immediately

NMS Group S.p.A. has announced the appointment of Andrew Curtis as Chief Strategy Officer reporting to the Group CEO, effective immediately. Andrew brings to NMS Group three decades of experience as a global corporate strategy and business leader from biotech and pharma sectors. He is based in the US, working from the US subsidiary (Nerviano Medical Sciences Inc.) in Boston just opened this month.
(Click the title for the complete article)

Nerviano Medical Sciences S.r.l. Expands US Presence

Nerviano Medical Sciences S.r.l. (NMS Srl), announced today that it has expanded its presence in the US with the creation of a new US subsidiary, Nerviano Medical Sciences Inc. Nerviano Medical Sciences Inc. is incorporated in Delaware State while the company’s activities will be mostly concentrated in the Boston, Massachusetts area. The US subsidiary is part of NMS Srl and its holding NMS Group’s aggressive transformation plan to fortify further the Group’s footprint and accelerate its pace in expanding in the world’s key biotech and pharmaceutical market.
(Click the title for the complete article)

Nerviano Medical Sciences S.r.l. Announces First Patient Dosed in Phase 1 Clinical Trial of NMS-812 for The Treatment of Relapsed Refractory Multiple Myeloma (MM).

NMS-812 is a novel potent oral inhibitor of PERK (PKR-like endoplasmic reticulum kinase) that also inhibits GCN2 (General Control Nonderepressible 2). PERK and GCN2 are effectors of the Integrated Stress Response (ISR), a pro-survival pathway exploited by cancer cells to survive stress. PERK is a key effector of the unfolded protein response (UPR) and GCN2 is a sensor of amino acid deficiency. Both proteins modulate the eIF2α/ATF4 axis promoting tumor survival and drug resistance as well as, via direct and indirect mechanisms, the immune response.
(Click the title for the complete article)

Nerviano Medical Sciences signs research agreement with Università del Piemonte Orientale, Faculty of Pharmaceutical Sciences

Nerviano, 28 June 2022
Nerviano Medical Sciences (NMS Srl) a member of NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancer, is pleased to announce the signing of the agreement with Università del Piemonte Orientale, faculty of Pharmaceutical Sciences in Novara (DSF), as part of the National Operational Programme on Research and Innovation 2014-2020 (Programma Operativo Nazionale (PON) – “RICERCA E INNOVAZIONE” 2014-2020). The Programme is the key instrument with which the Italian government contributes to the improvement of the quality of higher education and the enhancement of research, technological development and innovation.
(Click the title for the complete article)

BrYet Health Inc starts a Manufacturing Development Agreement with NerPharMa for its lead product candidate ML-016 against lung and liver metastases from different type of breast cancer.

Nerviano, 31 May 2022
BrYet Health Inc starts a Manufacturing Development Agreement with NerPharMa for its lead product candidate ML-016 against lung and liver metastases from different type of breast cancer. BrYet is an American biotechnology company based in Houston TX founded for the purpose of developing and bringing to market drugs for prevention and treatment of multiple types of metastatic cancer, based on a disruptive approach developed by Prof. Mauro Ferrari: Transport Oncophysics. BrYet will collaborate with our strategic production partner NerPharMa, a leading CDMO in oncology, to scale-up the drug substance manufacturing process and the finished product to supply material for clinical programs with potential upside to future world-wide commercial sales. The company’s goal is to start ML-016 clinical trials in the second half of 2023.
(Click the title for the complete article)

European Journal of Cancer this month published an article on the FIH study in patients with solid tumors conducted with the MPS1 compound NMS-01940153E discovered at NMS Srl.

Nerviano, 13 May 2022
Nerviano Medical Sciences (NMS Srl) a member of NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancer, is delighted to share the publication on the current issue of the European Journal of Cancer of the first-in-human (FIH) study conducted with the MPS1 inhibitor NMS-01940153E discovered in Nerviano (Schöffski et al.; European Journal of Cancer, Volume 169, 2022).
(Click the title for the complete article)

 Our Archive

MEDIA RELEASES & NEWS 2020
MEDIA RELEASES & NEWS 2019
MEDIA RELEASES & NEWS 2018
MEDIA RELEASES & NEWS 2020
MEDIA RELEASES & NEWS 2019
MEDIA RELEASES & NEWS 2018

 

Welcome and Check out our new motion picture!

WATCH OUR VIDEO